As the p53β/γ isoforms lack the canonical C terminus, this novel approach could also be used to eliminate loss-of-function or gain-of-function mutations in 2.7% of all cancers bearing these mutations downstream of p53 exon 9 (Table S3 and Fig. S8). Here, TP53 is linked to cancer.